Document is current
Any future updates will be listed below
-
Authors
Dhamodaran, Arunraj https://orcid.org/0000-0001-7711-9593
Chen, Xiaojing
Fellmer, Niklas
Agrawal, Deepti
Danner, Eric
Kühn, Ralf https://orcid.org/0000-0003-1694-9803
Blankenstein, Thomas https://orcid.org/0000-0002-3357-4321
- License Information
-
More Information
Article History
Received: 23 September 2024
Accepted: 19 June 2025
First Online: 1 July 2025
Competing interests
: T.B. and A.D. are inventors on a pending patent (PCT Nr. WO2023144087A1) jointly applied by the Max-Delbrück Center and T-knife Therapeutics with a title ‘A non-human mammal comprising in its genome at least two human leukocyte antigen (HLA) class I alleles, methods of making such mammal and uses thereof’ describing the mouse as a method tool for novel epitopes and TCR discovery. T.B. and A.D. is inventor on a pending patent (PCT Nr. WO2023139257A1) jointly applied by the Max-Delbrück Center and T-knife Therapeutics describing the KRAS-restricted TCR used in this study. A.D. and D.A. are former employees, and N.F. and E.D. are current employees of T-knife Therapeutics; they may hold stock and/or stock options in the company. T.B. is a founder and SAB (scientific advisory board) member of T-knife Therapeutics. The remaining authors declare no competing interests.
